Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 946

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 6
Chunk 946
---
 vesting on each of June 30, 2024, September
30, 2024, December 31, 2024, and March 31, 2025, subject in each case to the director’s Continuous Service (as defined in the 2020
Plan), through such dates. Vesting will terminate upon the director’s termination of Continuous Service prior to any vesting date.

There were no vested RSUs
outstanding as of March 31, 2025.

Recent Events 

Reverse
Split – Following the approval of a reverse stock split at a Special Meeting of Stockholders on May 13, 2025, our Board of Directors
approved a 1-for-8 reverse stock split or our outstanding shares of Common Stock, effective as of the close of business on June 6, 2023.
Accordingly, each 8 shares of outstanding common stock held by stockholders were combined into one share of common stock. Our authorized
common stock remained at 60,000,000 shares following the stock split. We issued 77 additional shares shares as a result of rounding up
fractional shares related to the reverse stock split.

 58 

On
June 2, 2025, a second patient was treated with the Hemopurifier at GenesisCare North Shore Hospital in Sydney, Australia. The
patient was treated with the Aethlon Hemopurifier for 4 hours in a single day and tolerated the procedure without complications. The patient
will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

RSU Grants

In April 2025, our Board of
Directors approved, pursuant to the terms of the Director Compensation Policy, the grant of the annual RSUs under the Director Compensation
Policy to each of the four non-employee directors of the Company then serving on the Board of Directors. The Director Compensation Policy
provides for a grant of stock options or $50,000 worth of RSUs at the beginning of each fiscal year for current non-employee directors
then serving on the Board of Directors, and for a grant of stock options or $75,000 worth of RSUs for a newly elected non-employee director,
with each RSU priced at the average for the closing prices for the five days preceding and including the date of grant, or $2.80 per share
for the April 2024 RSU grants. As a result, in April 2025 the four eligible directors were